CEACAM5 and colorectal carcinoma: CEA is a TAA commonly found to be overexpressed in CRC cells and is a target for preclinical and clinical studies for BiTE both as monotherapy (ClinicalTrials.gov: NCT02324257) or combination therapy (ClinicalTrials.gov: NCT02650713 and NCT03866239).82